We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.45 | 3.40 | 3.50 | 3.45 | 3.45 | 3.45 | 1,232,579 | 07:31:42 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -2.37M | -0.0262 | -1.32 | 3.11M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/8/2022 14:26 | Yes Franco tells me he tries to be as bearish as he can be so people sell and he can buy .Why else have stupid price targets!!He thinks we were born yesterday !! | nico115 | |
18/8/2022 14:23 | I told him to stop moaning and buy more on a second account over a month ago. Happy days then as he will have shares at 11p and whatever he is currently holding at. ;-) | ben gibbons | |
18/8/2022 14:02 | You still a buyer of 1m at 11p ?You're deramping not getting you anywhere as all on here know that when you deramp it's cos you want to buy in cheap No chance mate !! | nico115 | |
18/8/2022 10:38 | Why didn’t you put the Mr Hargreaves’s bit in or even the best bit Kings. Guess if I was you I’d leave this well alone Franco. | 412069 | |
18/8/2022 10:37 | VAL IS A DOG! | chesty1 | |
18/8/2022 09:52 | Ship is sinking fast. Cash burn continues. No other source of income. How the hell will Val fund a lab. !!!! Even the Thmx deal gives very little up front payment if it came off. Can you imagine the grief of them paying over milestone payments later down the line after this fiasco. Directors all getting paid for another year so no worries from their side. Next placing at 3-4p | francoismyname | |
18/8/2022 09:47 | Hopefully you will never buy Val againHopefully you are gone forever Good riddance | nico115 | |
18/8/2022 09:43 | Ye my hindsight trades have made 200,000% profit too lol | scepticalinvestor | |
18/8/2022 09:42 | No cash, no product, no idea | scepticalinvestor | |
18/8/2022 09:27 | Be very very aware of slater. Hes top slicing today. Complete predictable lol. Anyway Sold my last today in 50k and 100k chunks for another 10% profit. Combined trades 145% profit over 12 months approx. Only way to be successful at valirx is trade it imho. Buy and hold is lethal especially with valirx as they have never returned cash for shareholders. Last placing was ridiculous Suzy has let down lth. Anyway all the best to everyone. Kind regards J | jasonpugh | |
17/8/2022 17:06 | Hopefully ;-) | ben gibbons | |
17/8/2022 17:01 | He may have a load of rich mates. | 412069 | |
17/8/2022 16:37 | Someone very confident to drop 57k on 495000 shares plus all the other big buys. Great day and this was just on the back of Adam and his none official appointment. | ben gibbons | |
17/8/2022 12:15 | Is adam allowed to communicate with Theoremrx now in a more formal position and if so can he provide shareholders with his Personal opinions about this without violating nomad rules? | jasonpugh | |
17/8/2022 10:12 | Rns with adam is good. Mr market looked and turned over. The only way to wake him up is through a cash deal (Valirx first one in its existence!). Black swan events do happen you know. 😆 | jasonpugh | |
17/8/2022 07:42 | Brilliant Adam, well done & congratulations - I've never heard of this sort of move being made before. It's one I'm sure many a small company (and perhaps larger) might benefit from - assuming they had nothing to hide - which, by extension, suggests VAL don't. BZ ! | 801710245 | |
17/8/2022 07:13 | Yes agreed welcome move here | wapper | |
17/8/2022 07:03 | RnsAdam officially appointment as shareholder rep.Great move ;-) | ben gibbons | |
17/8/2022 03:53 | @Jasonpugh She needs the lab because its a way to drive regular revenues in the future and potentially avoid the current raise/spend/raise cycle - In principle its a good idea and they have the provision from the last resolutions to issue more shares to support it. I see this as a future positive. In the meantime, what the business is crying out for is stronger support at board level. I am not an advocate for removing Suzy, i think she is doing a sound job but lacks strong support and to compound this issue Kevin can't see this, he thinks to quote "she is a fierce negotiator" when in reality she is not. The handling of milestones for THX, them not paying any service fees over and the CENKOS warrants deal could all be avoided with stronger board support, they need to make two board appointments IMO one to replace the other Kevin that left and a second with strong negotiator skills. Will be interesting to see how events unfold but this will take some time to get right. GLA | porky9 | |
16/8/2022 16:49 | Theoremrx will be curiously looking at valirx chat to get a feel for sentiment. They will see that shareholders are not happy with suzys passive approach to 201 extension and will see this as weakness and will feel totally in control of negotiations especially with adam Hargreaves being introduced to lse chat as piggyback for questions. Unless suzy becomes more of a director than scientist then this will continue with Theoremrx and other potential companies in the future. .Suzy has changed. She used to be shareholder friendly but now it seems she has caught the George Morris virus of fame. The lab is her goal at all costs. To not inform valirx shareholders of progress. ie of theorenrx and 201.(even a partial bit of info). 301 Japanese company (pathetic timeframe) 401 Blackcat bio. (Her personal retirement nest egg)Bc201. Way too cloak and dagger. Power corrupts… | jasonpugh | |
16/8/2022 10:08 | Delisted here we come! | bonzo03 | |
15/8/2022 19:08 | Jason Pugh aka the beast of aim aka the cenkos warrior aka master yoda!When we last met I was but the learner! | ben gibbons | |
15/8/2022 19:07 | The game is a foot. | ben gibbons |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions